ClosedPublished 30 Jan 2026

Illumina, Inc. /
SomaLogic

Illumina expands its proteomics business with SomaLogic acquisition

Buy side: Illumina, Inc.
Buy sideIllumina, Inc.
Target: SomaLogic
TargetSomaLogic
Illumina, Inc. · 30 Jan 2026Source
Buy side: Illumina, Inc.
Buy sideIllumina, Inc.
Target: SomaLogic
TargetSomaLogic
01 / BuyerIllumina, Inc.
02 / TargetSomaLogic
Source for the buyer and target: Illumina, Inc.

For the buyer and target.

“Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology.”

Published 30 Jan 2026

Open the source
01

What happened

Illumina, Inc. completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The transaction included Standard BioTools Inc.’s aptamer-based and functional proteomics business. [01]

Illumina paid $350,000,000 in cash, subject to customary adjustments, and the transaction includes potential milestone payments and performance-based royalties. [01]

02

The source

Everything on this page comes from the source below, quoted word for word.

01
Source · Illumina, Inc.

Illumina expands its proteomics business with SomaLogic acquisition

This document is the source for the companies, stage and people on this page.

Open the source
03

Timeline

Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by Illumina, Inc.

    The source this page is built from.

    Open the source

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Get ProAlready a member? Sign in

Pro is open to everyone.